<DOC>
	<DOCNO>NCT02848326</DOCNO>
	<brief_summary>This study evaluate safety tolerability follow dos AGN-241689 : 10 mg daily ( QD ) , 30 mg QD , 30 mg twice daily ( BID ) , 60 mg QD , 60 mg BID prevention episodic migraine characterize dose/response relationship .</brief_summary>
	<brief_title>Efficacy , Safety , Tolerability Multiple Dosing Regimens Oral AGN-241689 Episodic Migraine Prevention</brief_title>
	<detailed_description />
	<mesh_term>Migraine Disorders</mesh_term>
	<criteria>Has least 1year history migraine without aura Age patient time migraine onset &lt; 50 year History 4 14 migraine/probable migraine headache day per month average 3 month prior Visit 1 Investigator 's judgment Demonstrated compliance ediary Has history migraine accompany diplopia decrease level consciousness , hemiplegic migraine , retinal migraine Has current diagnosis chronic migraine , new persistent daily headache , trigeminal autonomic cephalgia ( eg , cluster headache ) , painful cranial neuropathy Difficulty distinguish migraine headache headache Has history malignancy prior 5 year , except adequately treat basal cell squamous cell skin cancer , situ cervical cancer Has history gastric small intestinal surgery , disease cause malabsorption Has history hepatitis within previous 6 month Usage opioids barbiturates &gt; 2 days/month , triptans ergot ≥ 10 days/month , simple analgesic ( eg , aspirin , nonsteroidal antiinflammatory drug [ NSAIDs ] , acetaminophen ) ≥ 15 days/month 3 month prior Visit 1 Pregnant nursing female</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>